# A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

> **NCT06308406** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab； HRS-1167

## Key facts

- **NCT ID:** NCT06308406
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-15
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06308406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06308406, "A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06308406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*